Gyre Therapeutics stockholders elect directors, approve executive pay, auditor, and Series B conversion

GYRE THERAPEUTICS, INC.

Class II directors David M. Epstein, Ph.D. and Dan Weng, M.D. re-elected with ~70.2M and ~70.5M votes for, respectively.
Non-binding advisory vote on executive compensation approved with 70.5M votes for, 34,907 against.
Ratification of Grant Thornton Zhitong as independent auditor for FY2026 approved with 72.5M votes for.
Approval of conversion of Series B Convertible Preferred Stock into common stock passed with 70.5M votes for.
Broker non-votes reported for all proposals except auditor ratification (none).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

GYRE THERAPEUTICS, INC. shareholders approved Non-Binding Advisory Vote on Executive Compensation at the 2026-06-10 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 2: Non-Binding Advisory Vote on Executive Compensation The compensation of the Company’s named executive officers was approved, on a non-binding, advisory basis, as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,478,374 34,907 1,160 1,985,197

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

GYRE THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-10 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

The following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes • David M. Epstein, Ph.D. 70,160,332 354,109 1,985,197 • Dan Weng, M.D. 70,483,425 31,016 1,985,197

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

GYRE THERAPEUTICS, INC. shareholders approved Ratification of Independent Auditor at the 2026-06-10 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 3: Ratification of Independent Auditor The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows: Votes For Votes Against Abstentions Broker Non-Votes 72,487,596 11,626 416 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

GYRE THERAPEUTICS, INC. shareholders approved Approval of Conversion of Series B Preferred Stock at the 2026-06-10 meeting.

Outcome: passed
Meeting: 2026-06-10

Exact text from the filing

Proposal 4: Approval of Conversion of Series B Preferred Stock The issuance of shares of the Company’s common stock, par value $0.001 per share, upon conversion of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share, was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows: Votes For Votes Against Abstentions Broker Non-Votes 70,497,125 16,031 1,285 1,985,197

View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-025324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.